## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.86 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: declining volume (44% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($58.64)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: Morningstar | 20251130T203400 | Neutral | Relevance: 99%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential corporate governance reforms, return of funds, or other benefits. Shareholder participation is highlighted as important for improving company policies and enhancing shareholder value.

**2. DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit â€“ Contact Bronstein, Gewirtz and Grossman, LLC Today!**
- Source: WTRF | 20251130T070000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and certain officers for alleged violations of federal securities laws. The lawsuit claims DexCom made false and misleading statements regarding unauthorized material design changes to its G6 and G7 devices, which allegedly rendered them less reliable and posed health risks to users. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to join the lawsuit, with a lead plaintiff deadline of December 26, 2025.

**3. HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: Barchart.com | 20251130T203624 | Neutral | Relevance: 99%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. The firm encourages DexCom shareholders, particularly long-term ones, to contact them to discuss their legal rights, which may include seeking corporate governance reforms, the return of funds to the company, or other relief. Shareholder involvement is emphasized as a means to improve company policies and enhance shareholder value.

**4. DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: mypanhandle.com | 20251201T075500 | Neutral | Relevance: 99%
- Lieff Cabraser Heimann & Bernstein, LLP encourages investors of DexCom, Inc. (DXCM) who purchased securities between January 8, 2024, and September 17, 2025, to contact them regarding a securities class action. The lawsuit alleges that DexCom made false and misleading statements, specifically regarding unapproved design changes to its G6 and G7 continuous glucose monitoring systems that compromised accuracy and led to significant issues and declines in stock price. The deadline to apply to be lead plaintiff in this securities class action is December 26, 2025.

**5. DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm**
- Source: KLAS 8 News Now | 20251201T090800 | Neutral | Relevance: 99%
- The Schall Law Firm has announced a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged violations of securities laws, encouraging investors who purchased securities between January 8, 2024, and July 25, 2024, to join before October 21, 2024. The lawsuit claims DexCom made false and misleading statements about its growth and anticipated margins, particularly concerning its reliance on new customers while struggling with existing distribution channels. Investors who suffered losses due to these alleged misrepresentations are urged to contact the firm to discuss their rights.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 15.9% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (1 raises, avg +19%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 25.5 |
| Current P/E | 30.7 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 at 0.8% confirms short-term momentum alignment. AM_20 at 6.3% shows strong absolute momentum above own 20MA. Outperforming sector by 3.8pp, stock-specific strength. Below SMA200 (0.84x), long-term trend not supportive. MACD histogram positive (0.92), confirming momentum. RSI neutral at 54. Volume at 44% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.20% (CS: 90) | Strong |
| RSI_14 | 53.9 | Neutral |
| MACD Histogram | 0.92 | Bullish |
| vs SMA20 | 1.063x | Above |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 0.841x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $63.52
- **Stop Loss:** $58.64 (7.7% risk)
- **Target:** $73.28 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $9,718.56
- **Portfolio %:** 9.72%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*